ReviewJournal of asthma and allergy2015

Profile of anti-IL-5 mAb mepolizumab in the treatment of severe refractory asthma and hypereosinophilic diseases.

Francesco Menzella et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.